What a Partner Needs to Know Before Asking for More

In an initial partnering meeting I participated in, our prepared material focused on early research and development. The prospective partner wanted to understand the unknowns and potential problems we had not surfaced. We had prepared to explain the research; their concern was what remained unresolved and what further evaluation would have to examine.

In subsequent project communications, we began placing unresolved development issues and anticipated risks alongside the research. That change is the starting point for this article: a first summary should help the other side decide whether the next review is worth undertaking, including what may make that review difficult.

The Partner Wanted to Understand What Was Still Open

The research belonged in the conversation. But the partner's questions exposed what our material was missing: where our understanding stopped. They could see what we had done, but not what still needed to be worked through.

A first summary should help someone judge the commitment being asked of them. Scientific reasons for interest belong next to the unresolved issues that could shape the next review. Before taking another step, the recipient should be able to see what that step actually involves.

This matters in first outreach, especially in a non-confidential asset summary before a confidential disclosure agreement, or CDA. The recipient may have enough information to consider a meeting without having enough to judge the asset's broader scientific or commercial proposition. That is fine. The summary only needs to make the smaller commitment clear. Agreeing to examine an unresolved question is not the same as agreeing with the answer.

Define the Commitment Before Choosing the Evidence

Before choosing findings, write down the action you want the recipient to consider. A scoping meeting, consideration of a CDA, and review of a particular information package ask different things of the reader. They are not necessarily stages in a fixed sequence; the right route depends on the question and what information is available.

For a scoping meeting, say what the discussion is meant to clarify. Maybe the question is whether the opportunity fits the recipient's interests, or whether the collaboration itself is relevant. Give enough context for the meeting to have a subject. A broad invitation to explore possibilities forces the other side to define the meeting before deciding whether it is worth attending.

For consideration of a CDA, identify the question a confidential exchange could help examine and, where appropriate, what existing information would inform it. A CDA does not create scientific evidence. The disclosure process and agreement still require their own review.

If you are asking the partner to examine additional material, say what that material could clarify. If the issue is a limitation in the current interpretation, name the limitation and why it matters. The other side can then decide whether the information, and the people needed to review it, belong in the next discussion.

The evidence-boundary principle developed in Why Good Science Still Fails to Drive Decisions in Biotech still applies, but an external handoff adds another hurdle: the recipient first has to decide whether the review is worth doing at all. In the opening meeting, the unresolved issues mattered because they changed what further examination would involve. If the requested commitment is not named, even well-chosen evidence can leave the argument incomplete.

Make the Opportunity and the Basis for Fit Assessable

Start with a compact description of the opportunity: the asset type, intended use, current development status, and the collaboration being explored. These are not a universal disclosure standard. They are simply practical fields that help the recipient see what is actually on the table.

One useful scaffold is: [asset type] is being developed for [intended use], currently at [development status], and the team is exploring [collaboration scope]. If one of those fields is genuinely unresolved, leave it unresolved rather than filling the gap with language that only sounds complete.

If the collaboration scope is still open, say what needs to be clarified. There is a real difference between inviting a partner to help define a possible collaboration and asking them to evaluate one that is already defined. Both can be worthwhile, but they ask for different kinds of judgment.

Keep the present development proposition separate from possible future applications. A broader scientific possibility can help explain why an asset interests its team. It should not quietly become the opportunity the recipient is expected to accept today. Place future scope where its dependence on further evidence is apparent.

Then explain why this partner may have a reason to look. The scientific rationale answers why the asset merits consideration; the fit rationale answers why this recipient might care. If the recipient's priorities are not known, fit is still a hypothesis. That can itself be the purpose of the first discussion.

Once the asset and proposed collaboration are clear, the partner can decide who actually needs to look at it next and what additional context that review may require. If those basics remain unclear, another promising finding may add scientific interest without clarifying who should review it or what the review is meant to answer.

Watch for hidden expansion in the request. If the closing asks for interest in future applications that the body has not supported, the request has moved beyond the case the summary makes. Narrow the request or state the extra assumption. Scientific ambition can stay visible without carrying the whole case for the first discussion.

Show What Supports Interest and What Could Change It

For each central reason to keep evaluating the opportunity, connect the supporting observation to the interpretation it allows. Keep observed findings, the team's interpretation, and future development possibilities separate. Preserve the study context and material limitations needed to understand the claim, even when the full technical discussion belongs elsewhere.

A useful editing question is simple: can the recipient see why this finding matters to the next review? A result may justify a closer look without supporting the bigger claim. Let the reader accept the narrow implication without having to accept the broader story with it.

After that first meeting, we placed unresolved development problems and anticipated risks alongside the research in subsequent communications. Those issues belong with the evidence whose significance they could change. Giving risk its own page is insufficient if the reader still has to reconstruct its consequence for the opportunity.

Not every unresolved issue belongs in the first summary. The ones that matter are the ones that could change whether the partner wants or is able to keep looking, or materially change the interpretation under discussion. The relevant technical experts still have to judge that significance; the communication framework only makes the relationship visible.

Be precise about why information is missing. Sometimes it exists but sits outside the current disclosure scope. Sometimes it was simply left out of the summary. Sometimes it has not been generated yet. Those three situations lead to different next steps; calling all of them additional data needed blurs the difference.

A quick drafting test can keep the pieces connected: current evidence supports [bounded interpretation]; [material issue] remains open; the next review would examine [specific question] using [identified information]. If one of those brackets cannot be completed honestly, the gap is part of the handoff rather than something to write around.

If essential context cannot be conveyed within the current information scope, say so. The result may be a conversation only about how a review could happen, or no adequate basis to proceed yet. Hiding that constraint does not make the underlying risk smaller.

Some Questions Need New Evidence Before the Conversation Can Advance

In a separate antibody project I handled, the obstacle was different. I saw potential for broader applications. The prospective partner considered development in additional indications premature at the project’s maturity at that time. The broader possibility remained unresolved between those perspectives.

Later clinical results became available, and the project received renewed attention from the partner. I cannot attribute that renewed interest to the results alone. But the evidence available for the discussion had changed.

This is different from the opening meeting. There, the information existed and we changed what we surfaced. In the antibody project, the evidence itself changed. Better framing and new evidence are not interchangeable. The next step depends on which one the problem actually requires.

That distinction should shape the partnering request. The team can still believe in broader applications, but the current request should rest on what can be assessed now. Future scope can remain visible, with its dependence on further evidence made explicit.

There is no reason to treat that separation as a loss of ambition. It allows the recipient to examine the current opportunity without being asked to endorse every possible extension. It also gives the sender a more precise basis for later contact: explain what evidence has become available and which previously open question it may now inform.

If the missing basis requires a future result, another exchange of existing material cannot supply that evidence. A discussion may still clarify what would justify reassessment, but that is a narrower purpose. Sometimes the right next step is not to review more now, but to agree on what would make a later review worthwhile.

Build the Handoff Around the Question That Remains

The following situations call for different next steps. They can overlap, so the remaining question and the information available should guide the request.

If there is enough context to assess potential fit, the recipient can see the opportunity, the collaboration scope, and why it may be relevant. The next step can be a scoped discussion to test that fit. Showing up to the meeting is not technical endorsement.

Potential fit can coexist with an evidence gap. In that case, name the uncertainty and the existing information or expert review that could examine it, using the appropriate disclosure process. The information may still prove inconclusive; that possibility belongs in the handoff.

If the opportunity or its relevance is still unclear, establish what is being offered and why this recipient might consider it before asking for deeper review. A gap in support for a defined claim is different: that gap may itself give the review a clear subject.

If the evidence does not exist yet, say so. Name the future result that would justify reconsideration and the question it would inform. The substantive assessment may need to wait, although a discussion about what would trigger reassessment can still be useful.

And sometimes the right answer is to stop. A clear mismatch or an unresolved issue the recipient cannot accept may be enough to end the review. If a changed condition could justify revisiting the opportunity, name it. Another meeting or a CDA signature should not be the only definition of progress.

Applied to the opening meeting, this means surfacing unresolved development issues alongside the research so the partner can see what further review would involve. Applied to the antibody project, it means asking whether existing material can address the concern about maturity or whether reassessment needs later evidence. The next action is different because the underlying problem is different.

Before sending, write the action you are asking for above the summary. Read it from the recipient’s side: what would they need to examine, and what would agreeing to that step involve? Keep the context needed to interpret the evidence, including the unresolved issues that could change their assessment.

Then read the invitation one more time. If it still asks for a broad assessment while the body only supports a fit discussion, fix the invitation. The request should be the same in both places.